Meta‐Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes
Alimentary Pharmacology & Therapeutics · 2025-01 · 61 (1) · 8-31
DOI: 10.1111/apt.18373 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 04.11.2024. Verfasst von Sahand Karimzadhagh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Celiac Disease and Gluten Related Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University o…. Hauptthemen laut MEDLINE: Celiac Disease, Diabetes Mellitus, Type 1, Global Health. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 157 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Coeliac disease (CD) is common in patients with type 1 diabetes (T1D), but prevalence varies globally due to differing screening protocols. There have been substantial changes in screening guidelines over the past two decades.
Aim
To evaluate CD prevalence in patients with T1D, focusing on screening studies using antitissue transglutaminase (anti‐tTG) antibody.
Methods
We searched PubMed, Web of Science, Embase and Scopus for studies published up to 11 December 2023 using keywords related to CD and diabetes. We used random‐effects models for overall prevalence and all subgroups, with heterogeneity assessed using Cochran's Q test and the I 2 statistic performed in STATA 18.
Results
We included 106 articles involving 65,102 T1D patients across 40 countries. The pooled CD seroprevalence and confirmed CD prevalence were 9% (95% confidence interval, CI, 8%–10%) and 6% (95% CI 5%–7%), respectively. The prevalence was higher in females and children. Denmark, Saudi Arabia and Libya exhibited the highest prevalence (11%), followed by India and Egypt (10%). Belgium, France, Germany, South Africa and the United States had the lowest prevalence (2%). High‐income countries showed significantly a lower CD prevalence than middle‐income countries ( p = 0.03). Meta‐regression based on the Human Development Index (HDI) indicated that countries with higher HDI have lower seroprevalence and confirmed CD prevalence.
Conclusion
Approximately 1 in 16 patients globally and 1 in 12 patients in Asia and the Middle East with T1D has CD. We suggest that all patients with T1D should be screened for CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Celiac Disease and Gluten Related Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Sahand Karimzadhagh, Govind K Makharia, Mohammad Rostami-Nejad
Zitieren
APA
Karimzadhagh, S., Abbaspour, E., Shahriarinamin, M., Shamsi, P., Poursadrolah, S., Khorasani, M., Daghighi, M., Malek, A., Talesh, J. T., Makharia, G. K., & Rostami-Nejad, M. (2025). Meta‐Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes. Alimentary Pharmacology & Therapeutics, 61(1), 8-31. https://doi.org/10.1111/apt.18373
Vancouver
Karimzadhagh S, Abbaspour E, Shahriarinamin M, Shamsi P, Poursadrolah S, Khorasani M, et al. Meta‐Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes. Alimentary Pharmacology & Therapeutics. 2025;61(1):8-31. doi:10.1111/apt.18373
BibTeX
@article{Karimzadhagh2025,
author = {Karimzadhagh, Sahand and Abbaspour, Elahe and Shahriarinamin, Maryam and Shamsi, Pourya and Poursadrolah, Selvana and Khorasani, Mehrdad and Daghighi, Mahzad and Malek, Arash and Talesh, Jouan Taheri and Makharia, Govind K and Rostami-Nejad, Mohammad},
title = {Meta‐Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {61},
number = {1},
pages = {8--31},
doi = {10.1111/apt.18373}
}
EUVIMED